Resources

Expansion of the original 2015 approval makes Praluent a strong lipid-lowering candidate for patients with diabetes and other cardiovascular concerns.

The cause of many insulin errors is the use of abbreviations in written orders. The abbreviation “U” for “units” has often been misread as a zero, resulting in serious, tenfold overdoses. Recently, we heard about three new cases that illustrate other problems when abbreviations are used in insulin orders.

In this Exclusive Interview, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose in children with obesity.

In this Exclusive Interview transcript, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose and obesity in children.

In this Exclusive Interview, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Dexcom G6 CGM System and how the future of CGM will affect the way not only type 1, but also type 2 and prediabetes are treated.

In this Exclusive Interview transcript, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed  about the Dexcom G6 CGM System and the future of CGMs changing diabetes management for type 1, type 2, and even prediabetes. Click here to view the video interview. Steve Freed: This is Steve Freed …

I was working as a diabetes nurse in a hospital when a patient I was seeing asked me to find out why she experienced two recent hypoglycemic episodes. She came into the hospital…on a mixed insulin (75/25 ) 25 units before breakfast and 15 units before dinner. On reviewing her chart, I saw where the doctor had changed her insulin to Novolog before each meal, dose based on her blood sugars, and Lantus 30 units at bedtime.

In this Exclusive Interview, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about harnessing serotonin in the treatment of obesity and type 2 diabetes.

In this Exclusive Interview transcript, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about using serotonin in the treatment of obesity and type 2 diabetes.

In this Exclusive Interview, Mary de Groot talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about why people with diabetes have higher rates of depression, how depression differs from diabetes distress, and the effect of depression on diabetes management.